Table 3.
TNM stage-stratified analysis between CFP1 and 14-3-3 expression and overall survival time in 660 GC tissues
| Item | No. (%) | Median survival time, mo (95% confidence interval) | P |
|---|---|---|---|
| Stage I | |||
| CFP1 low expression | 47 (70.1) | – | 0.0301 |
| CFP1 high expression | 20 (29.9) | – | |
| 14-3-3 low expression | 49 (73.1) | 93.2 | 0.0190 |
| 14-3-3 high expression | 18 (26.9) | – | |
| Stage II | |||
| CFP1 low expression | 99 (70.7) | – | 0.0317 |
| CFP1 high expression | 41 (29.3) | 123.6 | |
| 14-3-3 low expression | 46 (32.9) | 123.6 | 0.0258 |
| 14-3-3 high expression | 94 (67.1) | 123.8 | |
| Stage III | |||
| CFP1 low expression | 214 (70.2) | 89.43 | < 0.0001 |
| CFP1 high expression | 91 (29.8) | 24.5 | |
| 14-3-3 low expression | 101 (33.1) | 25.9 | 0.0015 |
| 14-3-3 high expression | 204 (66.9) | 47.7 | |
| Stage IV | |||
| CFP1 low expression | 81 (54.7) | 20.03 | 0.0386 |
| CFP1 high expression | 67 (45.3) | 14.3 | |
| 14-3-3 low expression | 108 (73.0) | 11.4 | 0.0032 |
| 14-3-3 high expression | 40 (27.0) | 20.03 | |